Loading
Several treatments now work without chemotherapy, but most are given until the disease comes back. Giving them for a fixed time and stopping is the version patients would choose.
Two trials now recruiting bear directly on it: the National Cancer Institute comparison of fixed-duration mosunetuzumab against rituximab in low tumour burden follicular lymphoma, and the European trial of mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma. Neither is designed with time off treatment as a primary endpoint, which is the gap. The payer argument is the same as the patient argument here, which is unusual and worth using.
The authors' conclusion is that ibrutinib-rituximab should be considered a new standard-of-care option for first-line treatment of older patients with mantle-cell lymphoma. The subgroup split means it is clearly better than R-CHOP and roughly equivalent to bendamustine-rituximab.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
An off-the-shelf alternative to CAR-T for repeatedly relapsed follicular lymphoma: no apheresis, no manufacturing wait, and a complete response rate in the same range, at the cost of continued treatment rather than a single infusion.
Shares Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma, Maintenance and consolidation in lymphoma: where it works and where it does not, Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial, ENRICH and the tag lymphoma-evidence.
Shares RELEVANCE, Maintenance and consolidation in lymphoma: where it works and where it does not, Watchful waiting, and how it differs from active surveillance, Patients lack understanding, navigation and agency and the tag lymphoma-evidence.
Shares ENRICH, BTK (Bruton tyrosine kinase), Ibrutinib, CD20 and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, Patients lack understanding, navigation and agency, CD20, Rituximab and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, CD20, Rituximab, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares Maintenance and consolidation in lymphoma: where it works and where it does not, CD20, Rituximab, Mantle cell lymphoma and the tag lymphoma-evidence.
Shares Marginal zone lymphoma, CD20, Lenalidomide, Rituximab and the tag lymphoma-evidence.
Shares Watchful waiting, and how it differs from active surveillance, Marginal zone lymphoma, CD20, Rituximab and the tag lymphoma-evidence.